By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) ...

A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...

Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the ...

Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...

Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...

Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing ...

Cortigent will focus on neuromodulation devices while Vivani presses ahead with its weight loss drug implant. Vivani Medical ...

The company wants to create two focused companies dedicated to driving current and future value in their respective ...

Vivani Medical (VANI) announced that it intends to spin off Cortigent, a division that develops brain implant devices to help people recover ...

Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while ...

The Vivani Medical Inc. combination appears to be over less than three years since its inception after the company reported ...